<DOC>
	<DOCNO>NCT01357109</DOCNO>
	<brief_summary>The purpose study investigate oral treatment bosentan improve endothelium-dependent vasodilatation patient type 2 diabetes microangiopathy .</brief_summary>
	<brief_title>Effect Bosentan Endothelial Function Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Diabetes mellitus type 2 &gt; 2 year duration 2 . Albuminuria 1 . Age &gt; 80 year 2 . Myocardial infarction/unstable angina within three month prior randomisation 3 . Decompensated congestive heart failure functional class 3 4 . 4 . Changes dosage vasodilator drug precede six week 5 . Women fertile age . 6 . Impaired hepatic function ( 2 time upper normal limit aminotransferase ASAT ALAT ) 7 . Ongoing treatment glibenclamide , cyclosporin warfarin 8 . Any concomitant disease condition may interfere possibility patient comply complete study protocol 9 . Participant ongoing study 10 . Unwillingness participate follow oral write information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>